{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:00:20Z","timestamp":1790758820531,"version":"4.1.0"},"reference-count":108,"publisher":"Informa UK Limited","issue":"1-2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1080\/13543776.2024.2332661","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T09:27:46Z","timestamp":1710840466000},"page":"83-98","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Peroxisome Proliferator-Activated Receptor agonists and antagonists: an updated patent review (2020\u20132023)"],"prefix":"10.1080","volume":"34","author":[{"given":"Barbara","family":"De Filippis","sequence":"first","affiliation":[{"name":"Department of Pharmacy, G. d\u2019Annunzio University, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Granese","sequence":"additional","affiliation":[{"name":"Department of Drug Chemistry and Technology, \u201cSapienza\u201d University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4369-1772","authenticated-orcid":false,"given":"Alessandra","family":"Ammazzalorso","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, G. d\u2019Annunzio University, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154338"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24142545"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.02.028"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.4103\/2231-4040.90879"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.01.067"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2017.1280467"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.8b00574"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00189"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2007.02.003"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.033"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.2741\/4892"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom13081264"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2838-4"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205055"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12081523"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003796"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.013"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306185"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01285"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1057"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01648-1"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2130750"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.02.033"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000395"},{"key":"e_1_3_5_27_1","unstructured":"Univ Zhejiang Technology. PPAR-gamma ligand-4 5-diazafluorene-rhodanine conjugate preparation method and anti-tumor application thereof. CN113461684A. 2021."},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.624112"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17070999"},{"issue":"3","key":"e_1_3_5_30_1","first-page":"813","article-title":"The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms","volume":"31","author":"Zaytseva YY","year":"2011","unstructured":"Zaytseva YY, Wallis NK, Southard RC, et al. The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms. Anticancer Res. 2011;31(3):813\u201323.","journal-title":"Anticancer Res"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1933719114525265"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/494161"},{"key":"e_1_3_5_33_1","unstructured":"Univ Zhejiang Technology. Aminopyrimidine butenone derivative as PPAR-gamma modulator. CN111018834A. 2020."},{"key":"e_1_3_5_34_1","unstructured":"Univ Zhejiang Sience & Technology. PPAR gamma targeted glycyrrhetinic acid derivative and preparation method and application thereof. CN114014905A. 2021."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1934578X1300800335"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.9b03442"},{"key":"e_1_3_5_37_1","unstructured":"Yissum Res Dev Co of Hebrew Univ Jerusalem Ltd. Agonists of PPAR-\u03b4. WO2020110126A1. 2020."},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijch.201400072"},{"key":"e_1_3_5_39_1","unstructured":"Univ China Pharma. Compound with PPAR delta agonistic activity pharmaceutical composition and medical application. CN112479921A. 2021."},{"key":"e_1_3_5_40_1","unstructured":"Reneo Pharmaceuticals Inc. Methods of making a PPAR-delta agonist. WO2022115326A1. 2022."},{"key":"e_1_3_5_41_1","unstructured":"Reneo Pharmaceuticals Inc. Use of PPAR-delta agonists in the treatment of disease. WO2023147309A1. 2023."},{"key":"e_1_3_5_42_1","unstructured":"Kyungpook Nat Univ Ind Academic Coop Found. Novel PPAR antagonist and pharmaceutical composition for enhancing anti-cancer effect comprising the same. KR102431651B1. 2022."},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2007.02.004"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809010-00002"},{"key":"e_1_3_5_45_1","unstructured":"Medipure Pharmaceuticals Inc. Compounds for treating proliferator-activated receptors (PPAR) mediated diseases or conditions. WO2022221960A1. 2022."},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103803"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c02123"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c02002"},{"key":"e_1_3_5_49_1","unstructured":"Sichuan Kelun Biotech Biopharmaceutical Co Ltd. Aromatic compound pharmaceutical composition and use thereof. US11261170B2. 2022."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113807"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2010675"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081116"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-190864"},{"key":"e_1_3_5_54_1","unstructured":"Univ Auburn Ferris State Univ. Dual PPAR-\u03b4 and PPAR-\u03b3 agonists for treating disease. US10844003B1. 2020."},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.04.030"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00618"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01239"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.127969"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389557520666201023141326"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1061688"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.340"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.12.049"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.03.033"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.09.071"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.114061"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.13342"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.255216"},{"key":"e_1_3_5_68_1","unstructured":"Univ Guangdong Pharm. Novel FFA1 and PPAR alpha\/gamma\/delta quadruple agonist preparation method thereof and application of quadruple agonist as medicament. CN112759515A. 2021."},{"key":"e_1_3_5_69_1","unstructured":"The Second Peoples Hospital of Yunnan Province; Univ Guangdong Pharm. Application of FFA1 and PPAR delta dual agonist. CN113398123A. 2021."},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.652008"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45178-z"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0078"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2020.01.006"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0095"},{"key":"e_1_3_5_77_1","unstructured":"Univ Jiangsu. Application of combination of PPAR-alpha (peroxisome proliferator-activated receptor activator-alpha) and PD-1 antibody in preparation of tumor immunotherapy drugs. CN111035765A. 2020."},{"key":"e_1_3_5_78_1","unstructured":"Univ Jiangsu. Application of PPAR-delta antagonist combined with PD-1 antibody in preparation of tumor immune drug. CN110917347A. 2020."},{"key":"e_1_3_5_79_1","unstructured":"First Hospital Jilin Univ. Use of PPAR-delta inhibitor in combination with immunotherapeutic drug for preparing anti-tumor drug. WO2022166909A1. 2022."},{"key":"e_1_3_5_80_1","unstructured":"Univ Jiangsu. Application of PPARG activator and SIRP alpha antibody in preparation of tumor immune drugs. CN112138163A. 2020."},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-019-00469-5"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.60782"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1027235"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01197-w"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.12.002"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30490"},{"key":"e_1_3_5_87_1","unstructured":"Binzhou Medical College; Zhang Ning. PPAR gamma receptor agonist\/anticancer drug co-loaded tannic acid and phospholipid iron nanocomposite and preparation thereof. CN113952458A. 2022."},{"key":"e_1_3_5_88_1","unstructured":"Laviolette SR De Felice M Rusiniak R et al. Combination of cannabidiol and a PPAR agonist. WO2021203206A1. 2021."},{"key":"e_1_3_5_89_1","unstructured":"Mankind Pharma Ltd. Pharmaceutical combination of PPAR agonist(s) and sterol absorption inhibitor(s) and use thereof. WO2023026130A1. 2023."},{"key":"e_1_3_5_90_1","unstructured":"Bordeaux U. Centre Hospitalier Univ Bordeaux Inst Nat Sante Rech Med. Composition comprising PPAR-modulator and an urolithin derivative and uses thereof. EP4085906A1. 2022."},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2010.09.006"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040875"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1415-1"},{"key":"e_1_3_5_94_1","unstructured":"Kinarus Ag. Combinations of PPAR agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases. EP3820526A1. 2021."},{"key":"e_1_3_5_95_1","unstructured":"Antakly T PPAR-gamma activators HDAC inhibitors and their therapeutical usages. US11497723B1. 2022."},{"key":"e_1_3_5_96_1","unstructured":"Tyra Biosciences Inc. Therapies with PPAR agonists and FGFR4 inhibitors. WO2023225334A1. 2023."},{"key":"e_1_3_5_97_1","unstructured":"Laboratorios Silanes S.A. de C.V. Pharmaceutical combinations of statins and fibrates for the treatment and prevention of hyperlipidaemia and cardiovascular diseases. EP4180036A1. 2023."},{"key":"e_1_3_5_98_1","unstructured":"First Affiliated Hospital of Xiamen Univ Shenzhen Chipscreen Biosciences Co Ltd Chengdu Chipscreen Pharmaceutical Ltd. Use of PPAR agonist in preparation of drug for treating acute myeloid leukemia. WO2023072010A1. 2023."},{"key":"e_1_3_5_99_1","unstructured":"Genfit. PPAR-agonists for use in the treatment of liver failure. WO2022238445A1. 2022."},{"key":"e_1_3_5_100_1","unstructured":"Zhongshan Hospital Fudan Univ. Application of PPAR-gamma agonist rosiglitazone in sleep apnea related hypertension. CN115944633A. 2023."},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-3302"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.1115480"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00291.2009"},{"key":"e_1_3_5_104_1","unstructured":"Univ Zhongshan. Application of peroxisome proliferator-activated receptor agonist in preparation of anti-aging drugs. CN116999550A. 2023)"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2014.12.013"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01331"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00491"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201700703"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2017.05.008"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00666"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2024.2332661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T16:05:08Z","timestamp":1713369908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2024.2332661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":108,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1080\/13543776.2024.2332661"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2024.2332661","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}